Henry McCance’s wife Allison was diagnosed with Alzheimer’s Disease in 2000, and in 2004 he joined other philanthropists to found the Cure Alzheimer’s Fund. Over time, the fund has come to support more than 75 collaborative researchers around the world including Dr. Rudy Tanzi, at Mass General Hospital. As that collaboration grew, in 2018 Henry McCance and the McCance Foundation provided funding to establish the Henry and Allison McCance Center for Brain Health at Mass General Hospital.
Henry is Chairman Emeritus of Greylock Partners, one of the oldest and most successful venture capital firms. In 2004, Henry received the National Venture Capital Association’s Lifetime Achievement Award. He also received the Harvard Business School Award for Alumni Achievement in 2003, and was recognized as one of the country’s 10 Best Venture Capitalists by Forbes in 2000.
Henry came to Greylock in 1969 after serving for two years in the Office of the Secretary of Defense. He was responsible for Greylock’s early involvement in the software industry with his backing of market-leading firms including American Management Systems, Pansophic (acquired by Computer Associates), Cullinane (acquired by Computer Associates), McCormack and Dodge (acquired by D&B Software) and VM Software (acquired by Sterling Software, and now part of Computer Associates).
Today he is a partner of Fenway Sports Group, which owns the Boston Red Sox and Liverpool FC, and a member of the Advisory Board of Yale School of Management. He was formerly a Director of Cabot Corporation, a member of the Yale Investment Committee, and President of the Fishers Island Club.
Henry graduated from Harvard Graduate School of Business Administration with High Distinction, Baker Scholar, and from Yale University with a BA in economics, Magna Cum Laude and Phi Beta Kappa.
Three in five Americans will suffer a brain disease in their lifetime.
We're trying to get that number to zero.
Early diagnosis of Alzheimer's, dementia and stroke could save trillions.
Our work seeks to prevent and reduce the burden of brain disease.